应用动态血压监测仪及人体成分分析仪观察氨氯地平贝那普利片(Ⅱ)对原发性高血压患者的疗效

Observation of the efficacy of amlodipine besylate and benazepril hydrochloride tablets(Ⅱ)on patients with essential hypertension by ambulatory blood pressure monitor and human body component analyzer

目的 评价动态血压监测仪及人体成分分析仪在氨氯地平贝那普利片(Ⅱ)治疗原发性高血压患者疗效中的作用。方法 110例原发性高血压患者,入组前停用既往所有降压药,洗脱期间,饮食方式不变。2周之后接受氨氯地平贝那普利片(Ⅱ)治疗,监测并比较患者治疗前后动态血压参数(白天、夜间、24 h的收缩压和舒张压)、平滑指数、人体成分[骨骼肌质量、脂肪含量、骨骼肌质量指数(SMI)]。结果 治疗后,白天、夜间、24 h的收缩压分别为(132.58±11.22)、(120.23±12.83)、(126.10±8.11)mm Hg(1 mm Hg=0.133 kPa),均低于治疗前的(148.36±10.42)、(133.11±12.91)、(142.26±10.15)mm Hg,舒张压分别为(75.65±11.96)、(68.31±9.10)、(71.40±8.70)mm Hg,均低于治疗前的(85.03±10.98)、(77.85±10.84)、(83.92±9.89)mm Hg,治疗后的平滑指数(2.00±0.23)高于治疗前的(1.21±0.26),差异具有统计学意义(P<0.01)。患者治疗后的骨骼肌质量(35.75±6.84)kg、SMI(8.38±0.51)kg/m2均高于治疗前的(25.15±6.58)kg、(7.95±0.44)kg/m2,脂肪含量(18.83±4.15)kg低于治疗前的(23.12±4.51)kg,差异具有统计学意义(P<0.01)。结论 氨氯地平贝那普利片(Ⅱ)能有效平稳地降低原发性高血压患者的动态血压,且增加骨骼肌质量、降低脂肪含量,优化人体成分,值得临床推广。

Objective To evaluate the efficacy of amlodipine besylate and benazepril hydrochloride tablets(Ⅱ)on patients with essential hypertension by ambulatory blood pressure monitor and human body component analyzer[antihypertensive effect and stability of amlodipine besylate and benazepril hydrochloride tablets(Ⅱ)and its effect on body composition.]Methods In 110 patients with essential hypertension,all previous antihypertensive drugs were discontinued before enrollment,and diet remained unchanged during elution.2 weeks later,all patients were treated with amlodipine besylate and benazepril hydrochloride tablets(Ⅱ),and their ambulatory blood pressure parameters[daytime,nighttime,24 h systolic blood pressure and diastolic blood pressure],smoothness index,and body composition[skeletal muscle mass,fat content,and skeletal mass index(SMI)]were monitored and compared before and after treatment.Results After treatment,the daytime,nighttime,24 h systolic blood pressure were(132.58±11.22),(120.23±12.83)and(126.10±8.11)mm Hg(1 mm Hg=0.133 kPa),which were all lower than(148.36±10.42),(133.11±12.91)and(142.26±10.15)mm Hg before treatment;the daytime,nighttime,24 h diastolic blood pressure were(75.65±11.96),(68.31±9.10)and(71.40±8.70)mm Hg,which were lower than(85.03±10.98),(77.85±10.84)and(83.92±9.89)mm Hg before treatment;the smoothness index of(2.00±0.23)after treatment was higher than(1.21±0.26)before treatment;the difference was statistically significant(P<0.01).After treatment,the skeletal muscle mass was(35.75±6.84)kg and SMI was(8.38±0.51)kg/m2,which were higher than(25.15±6.58)kg and(7.95±0.44)kg/m2 before treatment;the fat content of(18.83±4.15)kg was lower than(23.12±4.51)kg before treatment;the difference was statistically significant(P<0.01).Conclusion Amlodipine besylate and benazepril hydrochloride tablets(Ⅱ)for patients with essential hypertension can effectively and stably reduce ambulatory blood pressure,increase skeletal muscle mass,reduce fat content and optimize body composition,which is worthy of clinical promotion.